TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”)
(Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes
for patients suffering from liver cancer through its advanced
delivery technology as well as an investigational immunotherapy,
nelitolimod, has announced a strategic partnership with Geo-Med,
LLC (“Geo-Med”), a certified Service-Disabled Veteran-Owned Small
Business (SDVOSB), to expand availability of the TriNav Infusion
System (“TriNav”) to U.S. Department of Veterans Affairs (VA)
medical centers nationwide.
“Fittingly, on the day honoring our veterans, we announce this
pivotal collaboration designed to expand access for U.S. veterans
to our proprietary Pressure-Enabled Drug Delivery™ (PEDD™)
approach. PEDD is enabled by TriNav, a promising technology with
the potential to improve liver cancer outcomes,” said Mary Szela,
Chief Executive Officer and President of TriSalus. “We are thrilled
to partner with Geo-Med to increase access to TriNav for veterans
battling liver cancer. This collaboration is closely aligned with
our mission to enhance patient outcomes, particularly for those who
have served our country.”
Geo-Med is a key supplier to the VA and the U.S. Department of
Defense (DOD) medical facilities. Their deep expertise in providing
high-quality medical products to the VA and DOD, along with their
insight into VA procurement, will be instrumental in ensuring that
TriNav reaches the veterans who need it most.
Hepatocellular carcinoma (HCC), the most common form of liver
cancer, occurs up to five times more frequently in U.S. veterans
than in the general population.1 The PEDD method has been shown to
improve therapeutic delivery to the tumor2, while simultaneously
decreasing non-target delivery3, offering a potentially more
effective treatment option for veterans battling liver cancer.
Mike Locke, Chief Executive Officer of Geo-Med, added, “We are
proud to collaborate with TriSalus to bring this innovative
delivery technology to veterans. Liver cancer is a particularly
aggressive disease, and by expanding access to TriNav, we’re
providing veterans with the latest advancements in treatment.”
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical
technology business providing disruptive drug delivery technology
with the goal of improving therapeutics delivery to liver and
pancreatic tumors.
The Company’s platform includes devices that utilize a
proprietary drug delivery technology and a clinical stage
investigational immunotherapy. The Company’s two FDA-cleared
devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™)
approach to deliver a range of therapeutics: the TriNav® Infusion
System for hepatic arterial infusion of liver tumors and the
Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
PEDD is a novel delivery approach designed to address the anatomic
limitations of arterial infusion for the pancreas. The PEDD
approach modulates pressure and flow in a manner that delivers more
therapeutic to the tumor and is designed to reduce undesired
delivery to normal tissue, bringing the potential to improve
patient outcomes. Nelitolimod, the Company’s investigational
immunotherapeutic candidate, is designed to improve patient
outcomes by treating the immunosuppressive environment created by
many tumors and which can make current immunotherapies ineffective
in the liver and pancreas. Patient data generated during
Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials
support the hypothesis that nelitolimod delivered via PEDD may have
favorable immune effects within the liver and systemically. The
target for nelitolimod, TLR9, is expressed across cancer types and
the mechanical barriers addressed by PEDD are commonly present as
well. Nelitolimod delivered by PEDD will be studied across several
indications in an effort to address immune dysfunction and overcome
drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive
technology development – TriSalus is committed to advancing
innovation that improves outcomes for patients. Learn more at
trinavinfusion.com and trisaluslifesci.com. Please also follow us
on X (formerly Twitter) and LinkedIn.
About Geo-Med, LLC
Geo-Med, LLC is a certified Service-Disabled Veteran-Owned Small
Business (SDVOSB) providing medical, surgical, and pharmaceutical
products to the VA and Department of Defense. With over two decades
of experience, Geo-Med is dedicated to delivering high-quality
healthcare products and improving the well-being of veterans and
active military personnel.
Forward-Looking Statements
Certain statements made in this press release are
“forward-looking statements” within the meaning of Section 27A of
the Securities Act and Section 21E of the Securities Exchange Act
of 1934, as amended, and are subject to the safe harbor created
thereby under the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “become,” “may,” “intend,” “will,” “expect,” “anticipate,”
“believe” or other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. These forward-looking statements may include, but are not
limited to, statements regarding the consummation of the Offer and
Consent Solicitation, the timing of the Expiration Date, the future
effectiveness of the registration statement on Form S-4, the
approval by the holders of Warrants of the Warrant Amendment and
subsequent entry into the Warrant Amendment, the effects of the
Offer on our capital structure and expected changes to the dilutive
impact of the Warrants. These statements are based on various
assumptions, whether or not identified in this press release, and
on the current expectations of the Company’s management and are not
predictions of actual performance. These forward-looking statements
are provided for illustrative purposes only and are not intended to
serve as, and must not be relied on by any investor as, a
guarantee, an assurance, a prediction or a definitive statement of
fact or probability. Actual events and circumstances are difficult
or impossible to predict and may differ from assumptions. Many
actual events and circumstances are beyond the control of the
Company. These forward-looking statements are subject to a number
of risks and uncertainties, including, without limitation: the
Company’s ability to successfully complete the Offer and Consent
Solicitation; the number of holders of Warrants that approve the
Warrant Amendment in the Consent Solicitation; the timing and
results of the SEC review of the registration statement on Form S-4
filed on May 24, 2024, if any; the Company’s ability to attract and
retain customers and expand customers’ use of the Company’s
products; risks relating to market, financial, political and legal
conditions; risks relating to the uncertainty of the projected
financial and operating information with respect to the Company;
risks related to future market adoption of the Company’s offerings;
risks related to the Company’s marketing and growth strategies;
risks related to the Company’s ability to acquire or invest in
businesses, products or technologies that may complement or expand
its products, enhance its technical capabilities or otherwise offer
growth opportunities; the effects of competition on the Company’s
future business; the risks discussed in the Company’s quarterly
report on Form 10-Q for the period ended March 31, 2024 under the
heading “Risk Factors”; and the risks discussed in the Company’s
Registration Statement on Form S-4 filed on May 24, 2024, under the
heading “Risk Factors” and other documents of the Company filed, or
to be filed, with the SEC. If any of these risks materialize or any
of the Company’s assumptions prove incorrect, actual results could
differ materially from the results implied by these forward-looking
statements. There may be additional risks that the Company
presently does not know of or that the Company currently believes
are immaterial that could also cause actual results to differ from
those contained in the forward-looking statements. In addition,
forward-looking statements reflect the Company’s expectations,
plans or forecasts of future events and views as of the date of
this press release. The Company anticipates that subsequent events
and developments will cause the Company’s assessments to change.
However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so except as required
by applicable law. These forward-looking statements should not be
relied upon as representing the Company’s assessments as of any
date subsequent to the date of this press release. Accordingly,
undue reliance should not be placed upon the forward-looking
statements.
___________________________ 1 Richman, VA Research Currents, May
2017 2 Titano, J. J. et al. End-hole Versus Microvalve Infusion
Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for
Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis.
Cardiovasc. Intervent. Radiol. 42, 560–568 (2019). 3 Pasciak, A.
S., McElmurray, J. H., Bourgeois, A. C., Heidel, R. E. &
Bradley, Y. C. The impact of an antireflux catheter on target
volume particulate distribution in liver-directed embolotherapy: a
pilot study. J. Vasc. Interv. Radiol. JVIR 26, 660–669 (2015).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241111316270/en/
For Media Inquiries: Stephanie Jacobson Argot Partners
610.420.3049 TriSalus@argotpartners.com
For Investor Inquiries: James Young SVP-Investor
Relations/Treasurer 847.337.0655
james.young@trisaluslifesci.com
TriSalus Life Sciences (NASDAQ:TLSI)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
TriSalus Life Sciences (NASDAQ:TLSI)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
